These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38500226)

  • 21. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
    Golub V; Reddy DS
    Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of cannabidiol in the treatment of epilepsy.
    Mazurkiewicz-Bełdzińska M; Zawadzka M
    Neurol Neurochir Pol; 2022; 56(1):14-20. PubMed ID: 35211946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Source of cannabinoids: what is available, what is used, and where does it come from?
    Specchio N; Pietrafusa N; Cross HJ
    Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
    García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V
    Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials.
    Bialer M; Perucca E
    Epilepsia; 2020 Jun; 61(6):1082-1089. PubMed ID: 32452568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Caregivers' Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study.
    Marshall J; Skrobanski H; Moore-Ramdin L; Kornalska K; Swinburn P; Bowditch S
    J Child Neurol; 2023 May; 38(6-7):394-406. PubMed ID: 37455396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CBD in the Treatment of Epilepsy.
    Borowicz-Reutt K; Czernia J; Krawczyk M
    Molecules; 2024 Apr; 29(9):. PubMed ID: 38731471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabinoids in treatment-resistant epilepsy: A review.
    O'Connell BK; Gloss D; Devinsky O
    Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2022; 68(10):1345-1357. PubMed ID: 36417631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
    Devinsky O; Thiele EA; Wright S; Checketts D; Morrison G; Dunayevich E; Knappertz V
    Acta Neurol Scand; 2020 Dec; 142(6):531-540. PubMed ID: 32592183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
    Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G
    Epilepsia; 2020 Sep; 61(9):1854-1868. PubMed ID: 32918835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
    Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
    Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
    Franco V; Perucca E
    Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabidiol in the Treatment of Epilepsy.
    von Wrede R; Helmstaedter C; Surges R
    Clin Drug Investig; 2021 Mar; 41(3):211-220. PubMed ID: 33559102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Wijnen B; Armstrong N; Ramaekers B; Witlox W; Westwood M; Fayter D; Ryder S; Buksnys T; Worthy G; Misso K; Grimm S; Kleijnen J; Joore M
    Pharmacoeconomics; 2020 Oct; 38(10):1043-1053. PubMed ID: 32514751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery.
    Del Pozo A; Barker-Haliski M
    Exp Neurol; 2023 Feb; 360():114288. PubMed ID: 36471511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
    Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
    Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis.
    Lattanzi S; Trinka E; Striano P; Zaccara G; Del Giovane C; Nardone R; Silvestrini M; Brigo F
    Epilepsia; 2020 Jun; 61(6):1090-1098. PubMed ID: 32452532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review.
    Balachandran P; Elsohly M; Hill KP
    J Gen Intern Med; 2021 Jul; 36(7):2074-2084. PubMed ID: 33515191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials.
    Nabbout R; Thiele EA
    Epileptic Disord; 2020 Jan; 22(S1):23-28. PubMed ID: 31916540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.